Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c00566 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Teng Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, C…. Hauptthemen laut MEDLINE: Alpha-Ketoglutarate-Dependent Dioxygenase FTO, Leukemia, Myeloid, Acute, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hangzhou Institute for Advanced Study, University of the Chinese Academy of Sciences.
Abstract (Originalsprache)
N6-Methyladenosine (m6A), the most prevalent mRNA modification, undergoes dynamic regulation mediated by the demethylase fat mass and obesity-associated protein (FTO), which is aberrantly overexpressed in acute myeloid leukemia (AML) and drives leukemogenesis. Based on the structure-guided optimization of our previously reported FTO inhibitor Dac85 and fluorescein, we developed Dac590, a tricyclic benzoic acid derivative with potent FTO inhibitory activity and improved pharmacokinetic properties. Dac590 exerts a robust antiproliferative effect on AML cells by suppressing oncogenic FTO signaling. Oral administration of Dac590 significantly inhibited xenograft tumor growth and prolonged survival in AML mouse models with no observed toxicity. Notably, Dac590 synergized with decitabine to enhance DNA hypomethylation and further improve the survival rates. Our study identifies Dac590 as a potent orally bioavailable FTO inhibitor and demonstrates a combinatorial strategy through dual epigenetic modulations for enhanced AML therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
- University of the Chinese Academy of Sciences, Beijing 100049, China.
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.
- Rname Pharmaceutical Technology (Shanghai) Co., LTD., Shanghai 430048, China.
ORCID-Profile: Ze Dong, Jianhua Gan, Cai-Guang Yang
Förderung
- National Natural Science Foundation of China
- Hangzhou Institute for Advanced Study, University of the Chinese Academy of Sciences
Zitieren
APA
Yang, T., Dong, Z., Du, R., Wang, Y., Liu, L., Xue, Y., Zhang, X., Liao, Y., Gan, J., Yu, X., Huang, Y., & Yang, C. G. (2025). Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00566
Vancouver
Yang T, Dong Z, Du R, Wang Y, Liu L, Xue Y, et al. Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00566
BibTeX
@article{Yang2025,
author = {Yang, Teng and Dong, Ze and Du, Rong and Wang, Yiqing and Liu, Lu and Xue, Yangyang and Zhang, Xi and Liao, Yonggang and Gan, Jianhua and Yu, Xiaoxuan and Huang, Yue and Yang, Cai-Guang},
title = {Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c00566}
}
EUVIMED